Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus

Keyphrases

• Type 2 Diabetes Mellitus (T2DM) 100%
• Type 2 Diabetic Patients 100%
• Add-on Therapy 100%
• Insulin Glargine 100%
• Glulisine 100%
• Monotherapy 31%
• Postprandial Glucose 21%
• Sulfonylurea 21%
• Plasma Glucose 15%
• Hemoglobin A1c (HbA1c) 15%
• Korean Patients 10%
• Adjusted Means 10%
• Biguanides 10%
• Japanese Patients 10%
• Large Reduction 5%
• Mealtime 5%
• Change from Baseline 5%
• Starting Dose 5%
• Intention-to-treat 5%
• Efficacy Endpoint 5%
• Glucose Control 5%
• Self-injected 5%
• Treatment Phase 5%
• Oral Antidiabetic Drugs 5%
• Mellitus 5%
• Baseline Therapy 5%
• Asymptomatic Hypoglycemia 5%
• Stable Baselines 5%
• Severe Hypoglycemia 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Add on Therapy 100%
• Insulin Glulisine 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Monotherapy 28%
• Sulfonylurea 19%
• Hemoglobin A1c 14%
• Hypoglycemia 9%
• Biguanide 9%
• Oral Antidiabetic Agent 4%